Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.
Introduction
Glioblastoma is the most common histological subtype of primary malignant brain tumour, with an annual incidence of about three per 100 000. 1 Glioblastomas are also the most aggressive form of primary brain tumour, with a dismal median survival of less than 12 months in population-based studies, and median survival of 15-17 months in clinical trials. [2] [3] [4] The standard treatment for patients with newly diagnosed glioblastoma consists of surgery followed by temozolomide chemoradiotherapy (radiotherapy with concomitant and adjuvant temozolomide). 2, 5 Other chemotherapeutics have little activity because of inherent resistance of glioblastoma cells against most cytotoxic drugs, or the inability of the drugs to cross an intact blood-brain barrier and reach their target. 6, 7 The DNA repair protein MGMT is an important prognostic factor in glioblastoma; its presence has been associated with decreased survival and resistance to alkylating chemotherapy. 8 Epigenetic silencing of the MGMT gene by promoter methylation can lead to it subsequently being unable to protect tumours from cytotoxic damage induced by temozolomide, and thus predicts benefi t from temozolomide chemotherapy. 9 In a pivotal randomised trial 10 investigating the value of temozolomide added to radiotherapy in patients with glioblastoma, median survival in patients with methylated MGMT promoter increased from 15·3 months (95% CI 13·0-20·9) with radiotherapy alone to 21·7 months (17·4-30·4) with radiotherapy and temozolomide (hazard ratio [HR] 0·51, 95% CI 0·31-0·84). However, patients with unmethylated MGMT promoter in the tumour showed only a marginal benefi t from addition of temozolomide, with a median survival of 12·7 months (95% CI 11·6-14·4) compared with 11·8 months (9·7-14·1) for patients treated with radiotherapy alone (HR 0·69, 95% CI 0·47-1·02).
Although glioblastomas very rarely metastasise, they frequently have local recurrence not only at the edge of resection but also at distant locations within the brain. Glioblastoma cells are characterised by high motility and invasiveness, requiring complex cell-matrix interactions. 11 Integrins are a family of cell-cell and cellextracellular matrix adhesion molecules, impli cated in various cellular processes (eg, cell survival, proliferation, migration, invasion, and angiogenesis), and thus can support tumour development. 12 In particular, αvβ3 and αvβ5 integrins are thought to be key mediators of crosstalk between tumour cells and the brain microenvironment in glioblastoma, and are overexpressed on tumour cells and vasculature. [13] [14] [15] Therefore, targeting of integrins and the tumour micro environment is considered a promising therapeutic strategy in glioblastoma. 15, 16 Cilengitide is a selective inhibitor of αvβ3 and αvβ5 integrins. 17 In phase 1/2 studies in patients with recurrent or newly diagnosed glioblastoma, cilengitide alone or in combination with temozolomide chemoradiotherapy was well tolerated and showed potential antitumour activity. [18] [19] [20] [21] [22] In a multicentre phase 1/2 study 20 of cilengitide added to standard temozolomide chemoradiotherapy in 52 patients with newly diagnosed glioblastoma, survival analyses suggested improved outcome compared with historical controls in patients with methylated MGMT gene promoter in the tumour, suggestive of synergy between cilengitide and temozolomide chemo therapy in chemosensitive tumours. Patients with and without MGMT promoter methylation had median progression-free survival of 13·4 and 3·4 months (HR 0·26, 95% CI 0·13-0·51, p<0·001), and a median overall survival of 23·2 and 13·1 months (HR 0·44, 95% CI 0·21-0·91, p=0·022), respectively. 20 Furthermore, fi ndings from two randomised phase 2 studies showed improved survival for patients with glioblastoma treated with higher dose cilengitide (2000 mg) than for those given a lower dose (500 mg), in both the newly diagnosed and recurrent setting. 19, 21 Preclinical models have also shown synergistic activity of cilengitide and irradiation. 23 In a randomised phase 3 trial, we aimed to assess cilengitide combined with standard treatment in a subgroup of patients with glioblastoma with methylated MGMT promoter. The investigation of patients with an unmethylated MGMT promoter in the tumour was subject of an exploratory phase 2 study (CORE) initiated shortly after our study began.
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Methods
Study design and participants
The CENTRIC trial was a global, multicentre, randomised, open-label, phase 3 trial. Eligible patients were aged 18 years or older with newly diagnosed, histologically confi rmed supratentorial glioblastoma (WHO grade IV), methylated MGMT promoter as determined by a central laboratory, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Additional inclusion criteria were written
Control
Step 1: Central MGMT methylation status assessment
Step 2: Randomisation Not eligible for study enrolment (Topic E6, 1996) , and applicable regulatory requirements. The study protocol and patient information sheets were approved by the institutional review boards or independent ethics committees of the participating institutions and competent authorities according to country-specifi c regulations. All patients gave written informed consent.
Randomisation and masking
Randomisation to the cilengitide group or control group was done centrally with use of an interactive voice response system. Patients were stratifi ed in blocks according to geographic region (ie, Europe, North America, and rest of world) and Radiation Therapy Oncology Group recursive partitioning analysis class. Because this study was open label, we did not apply any masking procedures to study investigators or patients. The independent review committee assessing progression-free survival was masked to treatment allocation, and the database remained masked to primary outcome variables for all parties until fi nal analysis.
Procedures
Before randomisation and after informed consent, an independent pathology review was done and the MGMT promoter methylation status of the tumour was centrally determined by the licensed laboratories of MDxHealth (Herstal, Belgium) with use of quantitative methylationspecifi c PCR, as described previously 25 with some modifi cations. In brief, DNA was isolated from formalinfi xed, paraffi n-embedded tumour samples using macrodissected sections; DNA was modifi ed with sodium bisulphite and subjected to methylation-specifi c PCR using β-actin as a reference gene (ACTB). Patients were classifi ed as MGMT methylated when the ratio of MGMT to ACTB was 2·0 or higher, calculated as (methylated MGMT/ACTB) × 1000 (the cutoff corresponding to the established nadir that separates methylated from unmethylated). 26 A minimum of 1250 copies of ACTB were required for a valid result, unless the copy number for methylated MGMT was ten or more, which was scored as MGMT methylated. We then randomly assigned eligible patients (ie, those with confi rmed methylated MGMT promoter and meeting other eligibility criteria) in a 1:1 ratio to receive either standard temozolomide chemoradiotherapy alone, or temozolomide chemoradiotherapy with added cilengitide (standard dose of 2000 mg intravenously twice weekly on days 1 and 4, beginning 1 week before starting temozolomide and radiotherapy; fi gure 1). 3 Radiotherapy consisted of 3D conformal radiotherapy and was given at 2 Gy per fraction, 5 days per week, for up to 6-7 weeks and a total of 60 Gy. Temozolomide 75 mg/m² was given orally 7 days per week throughout radio therapy (concomitant phase); thereafter, starting 4 weeks after the end of radio therapy (week 11), temozolomide 150-200 mg/m² was given for 5 days consecutively every 4 weeks for six cycles (adjuvant phase). 3 Cilengitide was continued for up to 18 months or until disease progression or unacceptable toxic eff ects. In case of fi rst occurrence of an unacceptable toxic eff ect thought to be related to study drugs, cilengitide treatment was suspended until recovery from the adverse event to grade 2 or lower. Thereafter, administration could be restarted at the investigator's discretion at a dose of 500 mg, and gradually increased in weekly intervals up to 2000 mg. Cilengitide treatment was discontinued permanently if the same severe toxic eff ect recurred. Crossover from the control to the cilengitide group was not allowed. Cilengitide was given as 1 h intravenous infusion starting 4 h before radiotherapy; temozolomide was given orally within 2 h after completion of cilengitide infusion and at least 1 h before radiotherapy.
Outcomes
The primary endpoint was overall survival. Secondary endpoints were progression-free survival and safety. We defi ned overall survival as time from randomisation until death, and progression-free survival as the duration from randomisation until fi rst report of progressive disease or death from any cause. Progression-free survival was assessed locally by investigators on the basis of gadolinium-enhanced MRI and according to the Macdonald criteria at 4 weeks after radiotherapy, then at 18, 26, and 34 weeks after randomisation, and every 12 weeks thereafter during the follow-up phase. In case of suspected pseudoprogression, investigators were advised to continue treatment per protocol and repeat imaging after 1-2 months. All imaging and corresponding clinical data were reviewed at the end of study recruitment by an independent review committee in a blinded manner. For this external review the Response Assessment in Neuro-Oncology (RANO), developed and recommended for clinical trials after this study's protocol initiation, was used. 27 We coded adverse events according to the Medical Dictionary for Regulatory Activities version 15.0, with severity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
Statistical analysis
We estimated overall survival and progression-free survival using the Kaplan-Meier method. Treatment groups were compared using a log-rank test stratifi ed for randomisation strata. A Cox proportional hazards model with stratifi cation according to randomisation strata was used to calculate treatment HRs and 95% CIs. No check of proportional hazards assumptions was planned per protocol. We did sensitivity analyses unstratifi ed and for the per-protocol set.
All outcome analyses were done on the intention-totreat population; safety was assessed on patients treated with at least one dose of cilengitide or who were exposed to radiotherapy or temozolomide (safety population). The study sample size was based on the assumption of a median overall survival of 23 months for the control group, an HR for the diff erence in overall survival between the experimental and control groups of 0·71, power of 80%, two-sided signifi cance level of 5%, and accrual of 24 months. Based on these assumptions, the target number of events was 266, expected after a 21-month follow-up, and planned sample size was 504 patients or 252 patients per group. A formal interim analysis for futility was planned after reporting of 25% of planned maximum number of events. All statistical analyses were independently done on mature data with a median followup of 29 months (IQR 25-35) by statisticians both at Merck KGaA, Darmstadt, Germany, and at the European Organisation for Research and Treatment of Cancer (EORTC) using SAS software version 9.2.
This study is registered with ClinicalTrials.gov, number NCT00689221.
Role of the funding source
This study was funded by Merck KGaA, Darmstadt, Germany. Study design, data analysis, and data interpretation were done collaboratively by the principal investigators, the EORTC, and the Merck study team. The steering committee oversaw the study. The principal investigators (RS and MW) had full access to and reviewed all data, and had fi nal responsibility for the decision to submit for publication. Data collection was done by a clinical research organisation mandated and funded by Merck.
Results
3471 patients were registered and screened for eligibility; of these patients, 3060 were assessed for MGMT methylation status. Patients were recruited at 146 study sites in 25 countries worldwide. 926 patients had glioblastoma with MGMT gene promoter methylation, including 382 patients who did not to continue to randomisation (fi gure 2). 545 patients were randomly assigned to a treatment group between Oct 31, 2008, and May 12, 2011, and constituted the intention-to-treat population. Patient baseline and demographic characteristics are summarised in table 1. We randomly assigned 272 patients to receive cilengitide twice-weekly in addition to standard temozolomide chemoradiotherapy (cilengitide group) and 273 to receive temozolomide chemoradiotherapy alone (control group). The median duration from operation or biopsy to randomisation was similar in both groups; the median time from surgery to start of radiotherapy was 6·2 weeks (IQR 5·3-7·0) in the cilengitide group and 5·4 weeks (IQR 4·6-6·1) in the control group (cilengitide treatment was to begin a week before radiotherapy). 263 (97%) patients in the cilengitide group and 258 (95%) patients in the control group received at least one dose of study medication, 
Number at risk Cilengitide group
Control group constituting the safety population. The main reason for discontinuation of treatment was disease progression both in the cilengitide group (n=157), and in the control group (n=153). 152 patients in the cilengitide and 151 in the control group received a further line of therapy after disease progression (appendix).
Patients in the cilengitide group (safety population) received cilengitide for a mean of 55·6 (SD 41·6) weeks, with a mean dose intensity of 3782 (481) mg/week; 216 (82%) patients received 90% or more of the planned cilengitide dose. 237 (90%) patients in the cilengitide group received 90% or more of the planned temozolomide dose, similar to the 237 (92%) patients in the control group. Furthermore, 199 (76%) patients in the cilengitide group and 197 (76%) in the control group received 90% or more of the planned dose of radiotherapy.
Median overall survival was 26·3 months (95% CI 23·8-28·8) in the cilengitide group and 26·3 months (23·9-34·7) in the control group (HR 1·02, 95% CI 0·81-1·29, p=0·86; fi gure 3A). 2-year survival did not diff er between treatment groups (56% in both; 95% CI 49-61 for the cilengitide group, 49-62 for the control group). Overall survival was much the same in the two treatment groups irrespective of stratifi cation according to baseline demographic characteristics and prognostic factors (fi gure 3B). Median progression-free survival as assessed by investigators was 13·5 months (95% CI 10·8-15·9) in the cilengitide group and 10·7 months (95% CI 8·1-13·3) in the control group (HR 0·93, 95% CI 0·76-1·13, p=0·46; fi gure 4A). The independent radiological review committee determined progression on average one assessment timepoint earlier in both groups, with a median progression-free survival of 10·6 months (95% CI 8·2-13·4) in the cilengitide group and 7·9 months (95% CI 5·9-12·5) in the control group (HR 0·92, 95% CI 0·75-1·12, p=0·41; fi gure 4B). Additionally, we noted no benefi t in overall survival or progression-free survival in the predefi ned patient subgroups for the addition of cilengitide to temozolomide chemoradiotherapy (fi gure 3).
Almost all patients had treatment-emergent adverse events (TEAEs; appendix). We noted grade 3 or 4 TEAEs in more than half of patients, but the occurrence was similar between treatment groups (169 patients each per group). At least one serious adverse event was reported by 138 (52%) patients in the cilengitide group compared with 115 (45%) patients in the control group. In the cilengitide group, 11 (4%) patients experienced TEAEs leading to death compared with nine (3%) patients in the control group. Three (1%) patient deaths in each study group were thought to be treatment related (appendix). In the cilengitide group, two (1%) patients died of pulmonary embolism, and one (<1%) died of aspiration pneumonia; none of these patients had myelosuppression. In the control group, one (<1%) patient died of pancytopenia and pneumonia, one (<1%) died of pneumonia after restarting temozolomide following pancytopenia, and one (<1%) died of septic shock without myelosuppression. We noted no cases of pneumocystis infection.
Discussion
Findings from this large, prospective, phase 3 trial investigating the fi rst-in-class integrin inhibitor cilengitide as antitumour therapy in combination with standard chemoradiotherapy did not show improved outcomes. Neither progression-free survival nor overall survival were signifi cantly prolonged, and an HR of 1·02 for overall survival suggests absence of any activity. The median overall survival of 26·3 months that we noted in both treatment groups is consistent with previous reports and experience in this population of patients with MGMT-methylated glioblastoma who have undergone gross total or partial tumour resection. Our fi ndings from this large multicentre trial lend support to the reported safety and tolerability of cilengitide in combination with standard treatment; we noted no indication of increased treatment-emergent toxic eff ects with the addition of cilengitide.
Our results raise the question of why the antitumour activity of cilengitide reported in previous phase 2 studies was not apparent in this trial. Indeed, the extensive phase 1 and phase 2 clinical development programme showed objective and durable responses in patients with recurrent glioblastoma, 18, 19 provided evidence for the drug reaching the tumour tissue, 22 and suggested a dosedependent trend for a potential improved overall survival for comparisons of a higher and lower cilengitide dose in randomised trials for patients with recurrent or newly diagnosed glioblastoma. 19, 21 At the same time, early development trials of cilengitide used either a lower dose (500 mg) or compared diff erent dosing regimens (500 vs 2000 mg cilengitide), but were done without standard-ofcare controls, and their comparisons were based on historical data. [18] [19] [20] [21] These designs contrast with that of this trial, in which a control group was included for comparison.
Cilengitide might induce some normalisation of the blood-brain barrier by itself, thus suggesting treatment response on imaging. In view of the short serum half-life of cilengitide of about 2-4 h, [18] [19] [20] 28 a schedule of continuous intravenous administration rather than a twice-weekly bolus could have been more appropriate. Although low concentrations of cilengitide have been linked to proangiogenic activity in experimental tumour models and changed traffi cking of αvβ3 integrin and VEGFR2, 29 we have previously argued that these experimental conditions probably do not represent the clinical scenario of administration of 2000 mg/m² of cilengitide. 30 This is consistent with our fi nding that the cilengitide group was similar to the control groups in terms of safety, and no detrimental eff ect was reported in any subgroup analysed in our trial. Functional imaging showing successful tumour targeting might also have been helpful. 31 Many other drugs have been explored in the past decade to improve outcomes for patients with glioblastoma. Inhibition of angiogenesis remains a prime treatment target. Similarly to cilengitide, randomised trials of bevacizumab added to standard temozolomide and radiotherapy in newly diagnosed glioblastoma did not extend overall survival, although progression-free survival was prolonged. 32, 33 These repeatedly failed eff orts underscore the complexity of this tumour type, and warrant improved preclinical models, investigation of combined target inhibition, and collaboration. More extensive and ideally controlled early-phase clinical trials are needed, and researchers should critically appraise the results before moving into defi nitive large-scale phase 3 studies. Despite the negative outcome of this trial, targeting of integrins remains a theoretically attractive target, because they are implicated in essential aspects of malignant disease (eg, angiogenesis, migration, and invasion) and their patterns Data are n (%). Table shows any grade reported in at least 10% of patients or grade ≥3 reported in at least 2% of patients. If a patient had more than one adverse event within a preferred term, the patient was counted once in the term. In this study, fatal adverse events were not classifi ed as grade 5; these events were recorded as grade 3 or 4 leading to death (appendix). in malignancies diff er from those of their parent tissues, potentially allowing selective targeting. 16 In the CENTRIC trial almost 3500 patients with a rare disease 1 were screened and molecularly assessed for eligibility during a 2-year period, underscoring the urgent need for novel and better treatments for patients with glioblastoma, and showing that a substantial number of patients are aff ected by a disease often excluded from clinical drug development programmes. Potentially detrimental treatment delays have been a concern for researchers seeking to molecularly characterise tumour types before allocation to specifi c treatments. In our trial, the median time to treatment start was 5-6 weeks, well within the accepted range of up to 7 weeks. 2 Similarly, in the recently reported AVAglio study, 96% of all patients started treatment within 4-7 weeks, 32 and in a trial assessing treatments for elderly patients, the median time to start of radiotherapy was 40-46 days. 26 In other publications, the time interval between surgery and treatment start was not reported. 33 In our trial, we noted no indication that the time interval between initial diagnosis and treatment start aff ected outcome.
The protocol was designed by academic teams of the EORTC and the Canadian Brain Tumor Consortium, in close collaboration with the manufacturer of cilengitide. Because this trial was conducted as a registration trial of an entirely new compound and a companion diagnostic, study sponsor ship and management was coordinated by Merck KGaA (Darmstadt, Germany), but investigators and representatives of the EORTC held the majority positions in the steering committee and were intimately involved in the study conduct and data interpretation. The principal investigators reviewed data for all randomly assigned patients, and statistical analyses were done independently by the study teams at Merck and EORTC. Moreover, this collaboration now allows continued long-term follow-up and expanded analyses of molecular tumour characteristics by EORTC-based platforms.
This trial has shown the feasibility of upfront central histological review and molecular testing with no substantial delay in an international multicentre trial setting, which is a prerequisite for further drug development towards personalised medicine. 
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Panel: Research in context
Systematic review
We screened PubMed and abstracts presented at clinical oncology meetings for reports of clinical trials investigating novel agents for newly diagnosed glioblastoma. Other than combined chemoradiotherapy (the current standard treatment of care), the literature review suggested that no established alternative treatment options are available for these patients, although several targeted agents and angiogenesis inhibitors are under investigation. Cilengitide showed activity in early phase trials, and effi cacy was believed best when combined with other active treatments. Patients with a methylated MGMT promoter were reported to have improved outcomes with current treatments.
Interpretation
We molecularly preselected patients with MGMT methylation status for a randomised comparative phase 3 trial, but the results from this trial did not show any improvement in outcome of patients with glioblastoma when cilengitide was added to standard chemoradiotherapy. The failure of cilengitide to improve outcomes in newly diagnosed glioblastoma emphasises the pitfalls of phase 3 trials based on limited phase 2 data and represents a drawback for integrin inhibition as a new approach to cancer therapy. We demonstrated that upfront molecular analyses and patient population enrichment is feasible. Successful collaboration between academia and industry performing a large clinical trial jointly while allowing for independence of the partners, separate statistical analyses, and long-term follow-up has been shown.
